Alpha 2.0
Login Register
» Articles » PMID: 15841079

Variability in Organ-specific EGFR Mutational Spectra in Tumour Epithelium and Stroma May Be the Biological Basis for Differential Responses to Tyrosine Kinase Inhibitors

Overview
Journal Br J Cancer
Specialty Oncology
Date 2005 Apr 21
PMID 15841079
Citations 29
Authors
F Weber
K Fukino
T Sawada
N Williams
K Sweet
R M Brena
C Plass
T Caldes
G L Mutter
M A Villalona-Calero
C Eng
Affiliations
Soon will be listed here.
Abstract

Organ-specific differences in epidermal growth factor receptor (EGFR) mutational spectra and frequencies were found in lung cancer and sporadic and BRCA1/2-related breast cancers. Additionally, we found a high frequency of EGFR mutations in the tumour stroma of these invasive breast carcinomas. Those organ-specific mutational spectra and potential targets in the cancer-associated stroma might influence the efficacy of TKI therapy.

Citing Articles

Multimodal scanning of genetic variants with base and prime editing.

Belli O, Karava K, Farouni R, Platt R Nat Biotechnol. 2024; .

PMID: 39533106 DOI: 10.1038/s41587-024-02439-1.

Role of EGFR and FASN in breast cancer progression.

Chaturvedi S, Biswas M, Sadhukhan S, Sonawane A J Cell Commun Signal. 2023; 17(4):1249-1282.

PMID: 37490191 PMC: 10713975. DOI: 10.1007/s12079-023-00771-w.

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.

Amelia T, Kartasasmita R, Ohwada T, Tjahjono D Molecules. 2022; 27(3).

PMID: 35164092 PMC: 8838133. DOI: 10.3390/molecules27030819.

Reciprocal priming between receptor tyrosine kinases at recycling endosomes orchestrates cellular signalling outputs.

Smith M, Ferguson H, Ferguson J, Zindy E, Kowalczyk K, Kedward T EMBO J. 2021; 40(14):e107182.

PMID: 34086370 PMC: 8447605. DOI: 10.15252/embj.2020107182.

Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials.

Maennling A, Tur M, Niebert M, Klockenbring T, Zeppernick F, Gattenlohner S Cancers (Basel). 2019; 11(12).

PMID: 31756933 PMC: 6966464. DOI: 10.3390/cancers11121826.

References
1.
Kurose K, Hoshaw-Woodard S, Adeyinka A, Lemeshow S, Watson P, Eng C . Genetic model of multi-step breast carcinogenesis involving the epithelium and stroma: clues to tumour-microenvironment interactions. Hum Mol Genet. 2001; 10(18):1907-13. DOI: 10.1093/hmg/10.18.1907. View
2.
Kurose K, Gilley K, Matsumoto S, Watson P, Zhou X, Eng C . Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet. 2002; 32(3):355-7. DOI: 10.1038/ng1013. View
3.
Dancey J, Freidlin B . Targeting epidermal growth factor receptor--are we missing the mark?. Lancet. 2003; 362(9377):62-4. DOI: 10.1016/S0140-6736(03)13810-X. View
4.
Huang S, Liu H, Li L, Ku Y, Fu Y, Tsai H . High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004; 10(24):8195-203. DOI: 10.1158/1078-0432.CCR-04-1245. View
5.
Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View